PCYC-1128-CA – A phase1b/2 study of ibrutinib combination therapy
in selected advanced gastrointestinal and genitourinary tumors –
bladder, colon, gastric, renal
What type of cancer? What stage?
Advanced GI cancer – gastric and colon
Who is eligible?
Patients who have received prior chemotherapy
How will I be treated?
Patients will receive ibrutinib with other chemotherapy or biologic therapy
S0820
S0820 – Phase III a double blind placebo-controlled trial of eflornithine
and sulindac to prevent recurrence of high risk adenomas and second primary
colorectal cancers in patients with stage 0-3 colon cancer
What type of cancer? What stage?
Colorectal cancers or high-rick adenomas - polyps.
Who is eligible?
Patients with stage 0, 1, 2, or 3 disease that is removed who desire prevention
How will I be treated?
This study looks at using two drugs for prevention – Sulindac, non-steriodal
anti-inflammatory, and eflornithine is a drug that has been shown in a
preclinical data to have a role in cancer prevention.
CX-839-008
CX-839-008 – A phase III, randomized, placebo controlled study of
Atezolizumab (Anti-PD-L1 Antibody) as monotherapy and in combination with
platinum chemotherapy with untreated locally advanced or metastatic urothelial carcinoma
What type of cancer? What stage?
Renal cell cancer
Who is eligible?
Patients with disease progression after first-line therapy
How will I be treated?
Adds CB-839 - a drug that inhibits tumor cell nutrient uptake - to treated
with Cabozantinib - a small molecule tyrosine kinase inhibitor.
For physicians: more information about this specific trial at
clinicaltrials.gov.
